



Human TNF α Monoclonal Antibody (Research Grade Infliximab Biosimilar)

Recombinant Monoclonal Human IgG1 Clone #FB016

Catalog Number: BIO-002

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human TNF α in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Infliximab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG1 Clone #FB016
Purification	Protein A/G purified from CHO cell culture supernatant
Immunogen	Human TNF α
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method
Formulation	0.2 μ m filtered solution in PBS

APPLICATION

	Recommended Concentration
Flow Cytometry	0.25 μ g/10 ⁶ cells
Neutralization	Measured by its ability to neutralize TNF α -induced cytotoxicity in the L-929 mouse fibroblast cell line. The neutralization dose is typically 2-12 ng/mL in the presence of 0.25 ng/mL Recombinant Human TNF α and actinomycin D.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/ml in sterile 1xPBS
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">• 12 months from the date of receipt, -20 to -70°C as supplied.• 1 month, 2 to 8°C under sterile conditions

BACKGROUND

Infliximab is a monoclonal anti-tumor necrosis factor alpha (TNF α) antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Infliximab is a TNF α blocker and a chimeric human/mouse monoclonal IgG1 antibody